Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities

Liu, Fei; Hidru, Tesfaldet Habtemariam; Gao, Ruiyuan; Lin, Yajuan; Liu, Ying; Fang, F.; Liu, Jiwei; Li, Huihua; Yang, Xiaolei; Xia, Yunlong

doi:10.1097/hjh.0000000000002277

Cited by 15 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, most patients with HCC had high grade hypertension (76.7%) associated with a higher prevalence of other concomitant CVDs. 59 Based on these data, although they cannot be extrapolated to other populations, a large number of patients with HCC present with contraindications to antiangiogenic treatment. Moreover, arterial hypertension is a frequently observed treatment-related AE, with an incidence of grade > − 3 arterial hypertension of 15-23%.…”

Section: Patients With Significant Cardiovascular Diseasementioning

confidence: 99%

Systemic treatment of HCC in special populations

Rimassa

Personeni

Czauderna

et al. 2021

Journal of Hepatology

View full text Add to dashboard Cite

Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirrhosis (Child-Pugh B and C), a significant bleeding history, vascular invasion or portal vein thrombosis, as well as the elderly, those on haemodialysis, and those after solid organ transplantation. The article highlights relevant knowledge gaps and current clinical challenges. To improve the safety and efficacy of HCC treatment in these subgroups, future trials should be designed to specifically include patients with comorbidities.

show abstract

Section: Patients With Significant Cardiovascular Diseasementioning

confidence: 99%

Systemic treatment of HCC in special populations

Rimassa

Personeni

Czauderna

et al. 2021

Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…DM was defined as, fasting blood glucose (FPG) ≥7.0 mmol/L, a self-reported history of DM or current diabetes treatment (14). Smoking was defined as current smoking status or a lifetime consumption of more than 100 cigarettes as described in existing studies (15).…”

Section: Clinical Measurements and Definition Of Explanatory Variablesmentioning

confidence: 99%

The Distribution of Cardiovascular-Related Comorbidities in Different Adult-Onset Cancers and Related Risk Factors: Analysis of 10 Year Retrospective Data

Liu

Tang

et al. 2021

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

Introduction: Understanding the epidemiology of cardiovascular disease (CVD) related comorbidity is a key strategy for improving the outcomes of patients with cancer. Therefore, this study aimed to assess the distribution of cardiovascular comorbidities and cardiovascular risk factors (CVRF) among five cancer sites.Methods: This is a single-centered, cross-sectional study performed in Dalian, China. Between 2008 and 2018, all newly diagnosed cancer in the First Affiliated Hospital of Dalian Medical University, China were screened. Clinical data were extracted from a comprehensive electronic health record system.Results: 35861 patients with lung, colorectal, gastric, breast, and thyroid cancer were collected retrospectively. The most prevalent CVDs in descending order were hypertension (21.9%), followed by coronary heart disease (6.5%), atrial fibrillation (2.9%), and heart failure (1%). The prevalence of hypertension significantly varies between lung (21.3%), colorectal (27.3%), gastric (22.5%), breast (16.7%), and thyroid cancer (22.4%) (P < 0.001). CVRF varies with cancer sites. Age, sex, total cholesterol, triglyceride, low-density lipoprotein cholesterol, systolic blood pressure, smoking, alcohol use, and diabetes mellitus (DM) are common risk factors associated with CVD at different cancer sites. The association between DM and presence of CVD was strong in breast (odds ratio [OR] = 4.472, 95% confidence interval [CI]: 3.075–6.504, P < 0.001), lung (OR = 3.943; 95% CI: 3.270–4.754, P < 0.001), colorectal (OR = 3.049; 95% CI: 2.326–3.996, P < 0.001), and gastric (OR = 2.508; 95% CI: 1.927–3.264, P < 0.001) cancer.Conclusion: Cancer patients had a significant burden of CVD and increased CVRF. The prevalence of CVRF and CVD comorbidity differ for cancer types. DM remains significantly associated with CVD at different cancer sites except for thyroid cancer.

show abstract

“…Any dysregulation in the function and structure of VEGF, can play a critical role in the pathogenesis of VSDs. Circulatory vasculature is under direct influence of growth factors like VEGF, any deviation from the normal function of this growth factor can lead to serious consequences [ 31 ]. From our findings, selected SNP rs36208048 of VEGF did not show statistical difference in allele frequencies between cases and controls despite this variant being located in the promoter region of gene which is an essential part for the normal function of the growth factor [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Study of variants associated with ventricular septal defects (VSDs) highlights the unique genetic structure of the Pakistani population

et al. 2022

View full text Add to dashboard Cite

Background Ventricular septal defects (VSDs) are one of the leading causes of death due to cardiac anomalies during the first months of life. The prevalence of VSD in neonates is reported up to 4%. Despite the remarkable progress in medication, treatment and surgical procedure for VSDs, the genetic etiology of VSDs is still in infancy because of the complex genetic and environmental interactions. Methods Three hundred fifty subjects (200 VSD children and 150 healthy controls) were recruited from different pediatric cardiac units. Pediatric clinical and demographic data were collected. A total of six variants, rs1017 (ISL1), rs7240256 (NFATc1), rs36208048 (VEGF), variant of HEY2, rs11067075 (TBX5) and rs1801133 (MTHFR) genes were genotyped by tetra-ARMS PCR and PCR–RFLP methods. Results The results showed that in cases, the rs1017 (g.16138A > T) variant in the ISL1 gene has an allele frequency of 0.42 and 0.58 respectively for the T and A alleles, and 0.75 and 0.25 respectively in the controls. The frequencies of the AA, TA and TT genotypes were, 52%, 11% and 37% in cases versus 21%, 8% and 71% respectively in the controls. For the NFATc1 variant rs7240256, minor allele frequency (MAF) was 0.43 in cases while 0.23 in controls. For the variant in the VEGF gene, genotype frequencies were 0% (A), 32% (CA) and 68% (CC) in cases and 0.0%, 33% and 67% respectively in controls. The allele frequency of C and A were 0.84 and 0.16 in cases and 0.83 and 0.17 respectively in controls. The TBX5 polymorphism rs11067075 (g.51682G > T) had an allelic frequency of 0.44 and 0.56 respectively for T and G alleles in cases, versus 0.26 and 0.74 in the controls. We did not detect the presence of the HEY2 gene variant (g.126117350A > C) in our pediatric cohort. For the rs1801133 (g.14783C > T) variant in the MTHFR gene, the genotype frequencies were 25% (CC), 62% (CT) and 13% (TT) in cases, versus 88%, 10% and 2% in controls. The ISL1, NFATc1, TBX5 and MTHFR variants were found to be in association with VSD in the Pakistani pediatric cohort whilst the VEGF and HEY2 variants were completely absent in our cohort. Conclusion We propose that a wider programme of genetic screening of the Pakistani population for genetic markers in heart development genes would be helpful in reducing the risk of VSDs.

show abstract

Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities

Cited by 15 publications

References 26 publications

Systemic treatment of HCC in special populations

Systemic treatment of HCC in special populations

The Distribution of Cardiovascular-Related Comorbidities in Different Adult-Onset Cancers and Related Risk Factors: Analysis of 10 Year Retrospective Data

Study of variants associated with ventricular septal defects (VSDs) highlights the unique genetic structure of the Pakistani population

Contact Info

Product

Resources

About